Webinar: Genomic profiling from initial assessment to detection of measurable residual disease (MRD): how NGS can rapidly deliver key insights for myeloid neoplasms
Dr. Bevan Tandon
Director of Hematopathology and Molecular Pathology, Pathline Labs
Myeloid neoplasms are a heterogeneous group of blood and bone marrow-based disorders, primarily including myelodysplastic syndromes (MDS), myeloproliferative neoplasms (MPN), and acute myeloid leukemia (AML).
Comprehensive molecular analysis is critical for characterizing myeloid samples, understanding disease pathology, detecting residual disease mutations, and potentially informing risk-adapted therapeutic strategies.
Next-generation sequencing (NGS) is a transformative molecular testing technology that rapidly and simultaneously analyzes multiple genetic biomarkers, providing a comprehensive genomic profile from a single test.
During this presentation, Dr. Bevan Tandon of Pathline Labs reviews ongoing studies in his laboratory using the Oncomine Myeloid Assay GX, an NGS-based test capable of delivering results in just 1-2 days.
He also shares his experience with the Oncomine Myeloid MRD Assays (RUO), a highly sensitive NGS test for measurable residual disease (MRD) assessment that can identify mutations occurring at very low frequencies. Dr. Tandon shares recent analytical data from his team and offers his perspective on the value of NGS in hematopathology studies.
Please fill out the form below to view this webinar.